Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
FMS
MCID: FBR047
MIFTS: 58

Fibromyalgia (FMS)

Categories: Muscle diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Fibromyalgia

About this section

MalaCards integrated aliases for Fibromyalgia:

Name: Fibromyalgia 12 73 43 36 54 42 3 44 15 62 17 70 32
Fibromyalgia-Fibromyositis Syndrome 43
Diffuse Myofascial Pain Syndrome 43
Myofascial Pain Syndromes 70
Myofascial Pain Syndrome 43
Fibromyalgia Syndrome 43
Fibromyositis 43
Fibrositis 43
Fms 43

Classifications:

MalaCards categories:
Anatomical: Muscle diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:631
KEGG 36 H01636
MeSH 44 D005356
NCIt 50 C87497
SNOMED-CT 67 1304004
ICD10 32 M79.7
UMLS 70 C0016053 C0027073
Sources

Summaries for Fibromyalgia

About this section
MedlinePlus : 42 What is fibromyalgia? Fibromyalgia is chronic condition that causes pain all over the body, fatigue, and other symptoms. People with fibromyalgia may be more sensitive to pain than people who don't have it. This is called abnormal pain perception processing. What causes fibromyalgia? The exact cause of fibromyalgia is unknown. Researchers think that certain things might contribute to its cause: Stressful or traumatic events, such as car accidents Repetitive injuries Illnesses such as viral infections Sometimes, fibromyalgia can develop on its own. It can run in families, so genes may play a role in the cause. Who is at risk for fibromyalgia? Anyone can get fibromyalgia, but it is more common in Women; they are twice as likely to have fibromyalgia Middle-aged people People with certain diseases, such as lupus, rheumatoid arthritis, or ankylosing spondylitis People who have a family member with fibromyalgia What are the symptoms of fibromyalgia? Common symptoms of fibromyalgia include Pain and stiffness all over the body Fatigue and tiredness Problems with thinking, memory, and concentration (sometimes called "fibro fog") Depression and anxiety Headaches, including migraines Irritable bowel syndrome Numbness or tingling in the hands and feet Pain in the face or jaw, including disorders of the jaw know as temporomandibular joint syndrome (TMJ) Sleep problems How is fibromyalgia diagnosed? Fibromyalgia can be hard to diagnose. It sometimes takes visits to several different health care providers to get a diagnosis. One problem is that there isn't a specific test for it. And the main symptoms, pain and fatigue, are common in many other conditions. Health care providers have to rule out other causes of the symptoms before making a diagnosis of fibromyalgia. This is called making a differential diagnosis. To make a diagnosis, your health care provider Will take your medical history and ask detailed questions about your symptoms Will do a physical exam May do x-rays and blood tests to rule out other conditions Will consider the guidelines for diagnosing fibromyalgia, which include A history of widespread pain lasting more than 3 months Physical symptoms including fatigue, waking unrefreshed, and cognitive (memory or thought) problems The number of areas throughout the body in which you had pain in the past week What are the treatments for fibromyalgia? Not all health care providers are familiar with fibromyalgia and its treatment. You should see a doctor or team of health care providers who specialize in the treatment of fibromyalgia. Fibromyalgia is treated with a combination of treatments, which may include medicines, lifestyle changes, talk therapy, and complementary therapies: Medicines Over-the-counter pain relievers Prescription medicines that were specifically approved to treat fibromyalgia Prescription pain medicines Certain antidepressants, which may help with pain or sleep problems Lifestyle changes Getting enough sleep Getting regular physical activity. If you have not already been active, start slowly and gradually increase how much activity you get. You may want to see a physical therapist, who can help you create a plan that is right for you. Learning how to manage stress Eating a healthy diet Learning to pace yourself. If you do too much, it can make your symptoms worse. So you need to learn to balance being active with your need for rest. Talk therapy, such as cognitive behavioral therapy (CBT), can help you learn strategies to deal with pain, stress, and negative thoughts. If you also have depression along with your fibromyalgia, talk therapy can help with that too. Complementary therapies have helped some people with the symptoms of fibromyalgia. But researchers need to do more studies to show which ones are effective. You could consider trying them, but you should check with your health care provider first. These therapies include Massage therapy Movement therapies Chiropractic therapy Acupuncture

MalaCards based summary : Fibromyalgia, also known as fibromyalgia-fibromyositis syndrome, is related to chronic pain and interstitial cystitis, and has symptoms including muscle weakness, fatigue and myoclonus. An important gene associated with Fibromyalgia is COMT (Catechol-O-Methyltransferase), and among its related pathways/superpathways are Peptide ligand-binding receptors and cAMP signaling pathway. The drugs Gabapentin and Etoricoxib have been mentioned in the context of this disorder. Affiliated tissues include liver, cortex and breast, and related phenotypes are behavior/neurological and homeostasis/metabolism

MedlinePlus Genetics : 43 Fibromyalgia is a common condition characterized by long-lasting (chronic) pain affecting many areas of the body. The pain is associated with tenderness that occurs with touch or pressure on the muscles, joints, or skin. Some affected individuals also report numbness, tingling, or a burning sensation (paresthesia) in the arms and legs.Other signs and symptoms of fibromyalgia include excessive tiredness (exhaustion); sleep problems, such as waking up feeling unrefreshed; and problems with memory or thinking clearly. People with fibromyalgia often report additional types of pain, including headaches, back and neck pain, sore throat, pain or clicking in the jaw (temporomandibular joint dysfunction), and stomach pain or digestive disorders such as irritable bowel syndrome. They have an increased likelihood of developing mood or psychiatric disorders including depression, anxiety, and obsessive-compulsive disorder. However, many people with fibromyalgia do not have a mental health condition.The major signs and symptoms of fibromyalgia can occur by themselves or together with another chronic pain condition such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, or systemic lupus erythematosus.

CDC : 3 Fibromyalgia (fi·bro·my·al·gi·a) is a condition that causes pain all over the body (also referred to as widespread pain), sleep problems, fatigue, and often emotional and mental distress. People with fibromyalgia may be more sensitive to pain than people without fibromyalgia. This is called abnormal pain perception processing. Fibromyalgia affects about 4 million US adults, about 2% of the adult population. The cause of fibromyalgia is not known, but it can be effectively treated and managed.

KEGG : 36 Fibromyalgia is a common and chronic pain disorder that predominantly affects women. It belongs to the group of rheumatic disorders of the soft tissues, and is characterised by widespread chronic pain, cognitive and affective disturbances and fatigue. The etiology and pathogenesis of fibromyalgia is uncertain. Genetic studies suggest an association with polymorphisms in serotonergic, dopaminergic, and catecholaminergic pathways involved in pain transmission and modulation. The disease is likely expressed in the presence of environmental trigger, which lead to expression of multiple genes that amplify pain perception in the pain processing pathway. Although there is no ultimate cure for fibromyalgia, some medications can alleviate symptoms of the disease.

PubMed Health : 62 About fibromyalgia: Fibromyalgia (also known as fibromyalgia syndrome or FMS) is a chronic condition that causes pain in various parts of the body. The pain may be felt in the skin, muscles and joints. Other typical symptoms include sleep problems, exhaustion and trouble concentrating. Although fibromyalgia has been recognized as an illness for 30 years now, people who have it are still sometimes made to feel like it’s all in their head. Part of the reason for this is that not many people are aware of fibromyalgia, and healthy people find it hard to understand. This often makes it even harder to live with the condition. Sometimes people who have fibromyalgia are told that the pain can’t be treated. But research has shown that there are indeed treatments that can relieve the typical symptoms. And many people learn to cope better with the pain over time. They find out what activities they can handle – and when to take things easier. It’s good to know that fibromyalgia isn’t a dangerous condition. It doesn’t affect people’s organs or life expectancy.

Wikipedia : 73 Fibromyalgia (FM) is a medical condition characterized by chronic widespread pain and a heightened pain... more...

Sources

Related Diseases for Fibromyalgia

About this section

Diseases related to Fibromyalgia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1075)
# Related Disease Score Top Affiliating Genes
1 chronic pain 32.2 PNOC OPRM1 COMT
2 interstitial cystitis 32.2 TACR1 IL6 CXCL8 BDNF
3 pre-eclampsia 31.4 TNF IL6 IGF1 CXCL8 CRP CRH
4 depression 31.3 SLC6A4 HTR3A HTR2A CRH BDNF
5 alexithymia 31.2 SLC6A4 IL6 CRP COMT
6 spondylitis 31.1 TNF IL6 CRP
7 chronic fatigue syndrome 31.0 TNF SLC6A4 POMC IL6 IGF1 HTR2A
8 spondyloarthropathy 1 31.0 TNF IL6 CRP
9 sexual disorder 31.0 SLC6A4 POMC IGF1 HTR2A BDNF
10 osteoarthritis 30.9 TNF IL6 CXCL8 CRP
11 acute stress disorder 30.9 SLC6A4 POMC IL6 CRP CRH BDNF
12 somatization disorder 30.8 SLC6A4 POMC IL6 CRH COMT
13 lyme disease 30.7 TNF IL6 CRP
14 personality disorder 30.7 SLC6A4 HTR3A HTR2A CRH COMT BDNF
15 obsessive-compulsive personality disorder 30.7 SLC6A4 HTR2A COMT
16 cystitis 30.6 TNF TACR1 IL6 CXCL8 CRP BDNF
17 irritable bowel syndrome 30.6 TNF SLC6A4 POMC IL6 HTR3A HTR2A
18 post-traumatic stress disorder 30.6 SLC6A4 PREP POMC HTR2A CRP CRH
19 restless legs syndrome 30.6 SLC6A4 SERPINA1 POMC COMT
20 hypochondriasis 30.6 SLC6A4 POMC HTR2A BDNF
21 mental depression 30.6 TNF SLC6A4 POMC IL6 HTR2A CRP
22 temporal arteritis 30.6 TNF IL6 CRP
23 paine syndrome 30.5 TNF TACR1 SLC6A4 PNOC OPRM1 IL6
24 brucellosis 30.5 TNF IL6 CXCL8 CRP
25 placenta disease 30.5 TNF IL6 CXCL8 CRP
26 synovitis 30.5 TNF IL6 CXCL8 CRP
27 juvenile rheumatoid arthritis 30.5 TNF IL6 CXCL8 CRP
28 familial mediterranean fever 30.4 TNF IL6 CXCL8 CRP
29 mood disorder 30.4 TACR1 SLC6A4 POMC NPY IL6 HTR3A
30 pustulosis of palm and sole 30.4 TNF CXCL8 CRP
31 dry eye syndrome 30.4 TNF IL6 BDNF
32 thyroiditis 30.4 TNF IL6 CRP
33 complex regional pain syndrome 30.4 TNF TACR1 POMC NPY IL6 CXCL8
34 relapsing-remitting multiple sclerosis 30.4 TNF IL6 CXCL8 BDNF
35 agoraphobia 30.4 SLC6A4 HTR2A CRH COMT
36 fasciitis 30.3 TNF IL6 CXCL8
37 panniculitis 30.3 TNF SERPINA1 CRP
38 serotonin syndrome 30.3 SLC6A4 HTR3A HTR2A
39 sleep apnea 30.3 TNF SLC6A4 IL6 IGF1 HTR2A CXCL8
40 somatoform disorder 30.3 TACR1 SLC6A4 OPRM1 IL6 CRH COMT
41 urethral syndrome 30.3 TNF IL6 CXCL8
42 bruxism 30.3 SLC6A4 HTR2A COMT
43 atherosclerosis susceptibility 30.3 TNF IL6 CXCL8 CRP
44 borderline personality disorder 30.3 SLC6A4 HTR3A HTR2A CRH COMT BDNF
45 constipation 30.3 TACR1 SLC6A4 OPRM1 NPY IL6 HTR3A
46 exanthem 30.3 TNF IL6 CXCL8 CRP
47 bipolar i disorder 30.3 SLC6A4 HTR2A COMT BDNF
48 conversion disorder 30.2 HTR2A CRH COMT BDNF
49 disseminated intravascular coagulation 30.2 TNF IL6 CRP
50 hyperprolactinemia 30.2 POMC IGF1 HTR2A

Graphical network of the top 20 diseases related to Fibromyalgia:



Diseases related to Fibromyalgia
Sources

Symptoms & Phenotypes for Fibromyalgia

About this section

UMLS symptoms related to Fibromyalgia:


muscle weakness; fatigue; myoclonus; back pain; myalgia; torticollis; pain; chronic pain; sciatica; muscle cramp; muscle rigidity; muscle spasticity; myofascial trigger point pain

MGI Mouse Phenotypes related to Fibromyalgia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.34 BDNF COMT CRH GRIN2D HTR2A HTR3A
2 homeostasis/metabolism MP:0005376 10.22 BDNF COMT CRH CRP GRIN2D HTR3A
3 endocrine/exocrine gland MP:0005379 10.18 BDNF COMT CRH HTR2A HTR3A IGF1
4 growth/size/body region MP:0005378 10.18 BDNF CRH GRIN2D HTR3A IGF1 IL6
5 adipose tissue MP:0005375 10.11 CRH GRIN2D IGF1 IL6 NPY OPRM1
6 immune system MP:0005387 10.03 COMT CRH CRP HTR3A IGF1 IL6
7 integument MP:0010771 9.93 BDNF CRH GRIN2D HTR3A IGF1 IL6
8 nervous system MP:0003631 9.8 BDNF COMT CRH GRIN2D HTR3A IGF1
9 renal/urinary system MP:0005367 9.23 COMT CRH HTR3A IGF1 IL6 NPY
Sources

Drugs & Therapeutics for Fibromyalgia

About this section

PubMed Health treatment related to Fibromyalgia: 62

Many people who have fibromyalgia avoid physical activity for fear of making the pain worse or overdoing it. But research has shown that exercise and gentle sports (e.g. cycling or Nordic walking) can improve their wellbeing, strengthen their body and relieve the pain somewhat. So they are an important part of the treatment . Certain medications have been proven to greatly reduce fibromyalgia pain in some people. These include amitriptyline , duloxetine , milnacipran and pregabalin . They all influence certain chemical messengers that also affect how we feel pain. These drugs were originally developed for the treatment of depression or epilepsy . When used in the treatment of fibromyalgia, though, they aren’t used for their antidepressant or anti-epileptic effects. Conventional painkillers such as diclofenac , ibuprofen or acetaminophen (paracetamol) generally aren’t recommended for the treatment of fibromyalgia. Many people with fibromyalgia find certain types of physical therapy to be pleasant, especially resting and/or moving in warm water. Some also say that going to the sauna or having gentle massages help. Multimodal pain management can be a good idea, particularly if the fibromyalgia pain is strong. This approach combines movement, relaxation and pain management techniques used in cognitive behavioral therapy (CBT). CBT and other psychological treatments can help people to cope better with pain and other symptoms in everyday life. Medication can be used as well. If someone also has other illnesses such as arthritis or psychological problems such as depression , it’s important to treat those conditions too.

Drugs for Fibromyalgia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 326)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
2
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
3
Apremilast Approved, Investigational Phase 4 608141-41-9 11561674
4
Perphenazine Approved Phase 4 58-39-9 4748
5
Trazodone Approved, Investigational Phase 4 19794-93-5 5533
6
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
7
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
8
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
9
Sodium citrate Approved, Investigational Phase 4 68-04-2
10
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
11
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
12
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
13
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
14
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
15
Flunarizine Approved Phase 4 52468-60-7 941361
16
Amitriptyline Approved Phase 4 50-48-6 2160
17
Acetaminophen Approved Phase 4 103-90-2 1983
18
Citalopram Approved Phase 4 59729-33-8 2771
19
Ibuprofen Approved Phase 4 15687-27-1 3672
20
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
21
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
22
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
23
Ethanol Approved Phase 4 64-17-5 702
24
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
25
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
26
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 644073 40400
27
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
28
Promethazine Approved, Investigational Phase 4 60-87-7 4927
29
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
30
Suvorexant Approved, Investigational Phase 4 1030377-33-3
31
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
32
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
33
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
34
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
35
Dexetimide Withdrawn Phase 4 21888-98-2
36 Cyclooxygenase 2 Inhibitors Phase 4
37 Antiemetics Phase 4
38 Antipsychotic Agents Phase 4
39 Quetiapine Fumarate Phase 4 111974-72-2
40 Central Nervous System Stimulants Phase 4
41 Cytochrome P-450 Enzyme Inhibitors Phase 4
42
Histamine Phosphate Phase 4 51-74-1 65513
43 Histamine H1 Antagonists Phase 4
44 Histamine Antagonists Phase 4
45 Citrate Phase 4
46 Anesthetics, Intravenous Phase 4
47 Anesthetics, General Phase 4
48 Excitatory Amino Acid Antagonists Phase 4
49 Anesthetics, Dissociative Phase 4
50 Trace Elements Phase 4

Interventional clinical trials:

(show top 50) (show all 877)
# Name Status NCT ID Phase Drugs
1 An Eight Week, Double-Blind Efficacy Study of Cyclobenzaprine ER (Amrix TM) Augmentation to Alleviate Fibromyalgia Fatigue and Muscle Pain Unknown status NCT01041495 Phase 4 cyclobenzaprine ER (AMRIX);placebo
2 Study Proposal - A Randomized Double-blinded Study Comparing Adding Etoricoxib Versus Placebo to Female Patients With Fibromyalgia-analysis of Organic and Psychiatric Measures Unknown status NCT00755521 Phase 4 etoricoxib
3 Low Dose Naltrexone for Treatment of Pain in Patients With Fibromyalgia - Effect Via a Central Mechanism? A Randomized, Double-blinded, Placebo-controlled, Crossover Study. Unknown status NCT02806440 Phase 4 Low dose naltrexone;Placebo
4 Open Label Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia Unknown status NCT03422640 Phase 4 Apremilast
5 The Impact of Perioperative Gabapentin on Chronic Groin Pain After Inguinal Hernia Repair Unknown status NCT02419443 Phase 4 Gabapentin;Placebo
6 Fixed Versus Flexible Dosing of Pregabalin in Patients With Fibromyalgia Completed NCT01226667 Phase 4 Pregabalin
7 Pool-based Exercise in Fibromyalgia Management: a Prospective Randomized Comparison Between Stretching and Ai Chi Completed NCT00550641 Phase 4
8 A Randomized Controlled Trial Comparing the Efficay and Tolerability of Ai Chi Versus Stretching in Fibromyalgia Management: a Six Months Study Completed NCT00600574 Phase 4
9 A Randomized, Pilot Clinical Trial to Assess the Comparative Efficacy and Tolerability of Quetiapine XR Versus Amitriptyline for the Treatment of Patients With Fibromyalgia Completed NCT00766350 Phase 4 amitriptyline;quetiapine
10 Open Label Trial Concerning the Effectiveness of Trazodone in the Treatment of Fibromyalgia (Phase I) and Its Augmentation With Pregabalin in Trazodone Partial Responders (Phase II) Completed NCT00791739 Phase 4 trazodone, pregabalin
11 The Study of Heart Rate Variability in Patients With Fibromyalgia - Effects of Strengthening Exercises Completed NCT02004405 Phase 4
12 An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue Completed NCT00678691 Phase 4 armodafinil;placebo
13 The Efficacy of Topical Thiocolchicoside in Cervical Myofascial Pain Syndrome: Triple-Arm, Single-Blind, Randomized, Prospective, Phase IV Clinical Study Completed NCT00272532 Phase 4 Thiocolchicoside
14 Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy, Alone or in Combination: a Single-blind, Randomized, Controlled Clinical Trial. Completed NCT01250184 Phase 4 Lidocaine injection
15 Paroxetine-CR (Paxil-CR) in the Treatment of Patients With Fibromyalgia Syndrome: A Randomized, Double Blind, Parallel Group, Flexible Dose, Placebo Controlled Trial. Completed NCT00610610 Phase 4 Paroxetine CR;Placebo
16 A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and Tolerability of Quetiapine Fumarate Sustained Release(Seroquel SRTM) in the Treatment of Major Depression With Comorbid Fibromyalgia Syndrome. Completed NCT00675896 Phase 4 Quetiapine Fumarate Sustained Release;Placebo
17 An Open-Label Pilot Study to Assess Potential Mechanisms for Fibromyalgia in Peripheral Tissue Innervation That Could Predict Therapeutic Responsiveness to Milnacipran Completed NCT01125423 Phase 4 Milnacipran
18 A Pilot Study on the Combined Use of Cognitive Behavioral Therapy (CBT) and Milnacipran Completed NCT01038323 Phase 4 Educational with milnacipran
19 A Randomized, Double-Blind Comparison of Duloxetine 30 mg QD and Placebo in Adult Patients With Fibromyalgia Completed NCT00965081 Phase 4 Duloxetine;Placebo
20 Eszopiclone in the Treatment of Insomnia and Associated Symptoms of Fibromyalgia Completed NCT00392041 Phase 4 Eszopiclone;placebo
21 Quetiapine Compared With Placebo in the Management of Fibromyalgia Completed NCT01458964 Phase 4 Quetiapine
22 The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia Completed NCT01234675 Phase 4 Milnacipran;Placebo
23 A Randomized, Double-blind,Placebo-controlled, Two-way Crossover Study to Evaluate the Effect of Milnacipran on Pain Processing and Functional Magnetic Resonance Imaging Activation Patterns in Patients With Fibromyalgia Completed NCT01173055 Phase 4 milnacipran;Placebo
24 Randomized, Double-blind, Placebo-controlled Trial to Measure the Efficacy and Safety of Vitamin D3 in Patients With Fibromyalgia. Completed NCT03369379 Phase 4 D3 Vitamin
25 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Switch Study to Evaluate the Safety, Tolerability and Efficacy of Milnacipran in Patients With an Inadequate Response to Duloxetine for the Treatment of Fibromyalgia Completed NCT01077375 Phase 4 Placebo;Milnacipran
26 Combining N-of-1 Trials to Assess Fibromyalgia Therapies Completed NCT00000428 Phase 4 Amitriptyline;Amitriptyline plus Fluoxitine
27 Quetiapine (Seroquel XR) for the Treatment of Fibromyalgia: a Clinical and Mechanistic Pilot Study Completed NCT00983320 Phase 4 quetiapine;placebo
28 A Pilot Study on the Use of Nociceptive Flexion Reflex for Fibromyalgia Completed NCT00965601 Phase 4
29 Effects of a 12 Week Milnacipran 200 mg Treatment on Pain Perception and Pain Processing in Fibromyalgia - An Open Label Study Completed NCT01288807 Phase 4 Milnacipram
30 A 6-month, Open-label, Safety Trial Of Pregabalin In Adolescent Patients With Fibromyalgia Completed NCT01020526 Phase 4 pregabalin
31 A 15 Week, Randomized, Double Blind, Parallel-group, Placebo-controlled, Flexible-dose, Safety And Efficacy Study Of Pregabalin In Adolescents (12-17 Years Old) With Fibromyalgia Completed NCT01020474 Phase 4 placebo;pregabalin (Lyrica)
32 Perception of Discomfort and Psychosocial Difficulties in People With Diagnosis of Fibromyalgia and Predominant Neck Pain Completed NCT02078791 Phase 4 Botox infiltration
33 Ultracet (Tramadol HCL [37.5 mg]/Acetaminophen [325 mg]) Combination Tablets in the Treatment of the Pain of Fibromyalgia Completed NCT00766675 Phase 4 Tramadol hydrochloride;Acetaminophen
34 Effectiveness of Strengthening Exercises Using the Swiss Ball for Patients With Fibromyalgia: a Randomized Controlled Trial Completed NCT02063750 Phase 4
35 A Multicenter, Randomized, Double-blind, Placebo-Controlled Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia in Patients Receiving Long-term Milnacipran Treatment Completed NCT01014585 Phase 4 Placebo;Milnacipran
36 Flexible Dosed Duloxetine Versus Placebo in the Treatment of Fibromyalgia Completed NCT00673452 Phase 4 duloxetine hydrochloride;placebo
37 Ambulatory Infusions of Lidocaine and Ketamine for Management of Chronic Pain: an Observational Prospective Study Completed NCT04123652 Phase 4 Lidocaine Hydrochloride 2% Intravenous Solution, DIN 02421992
38 Probe Study to Evaluate the Efficacy of Botulinum Toxin Serotype A Injections for Cervicobrachial Myofascial Syndrome Completed NCT00241215 Phase 4 Botulinum toxin serotype A
39 The Serotonin Receptor Type 3 Antagonist Granisetron as a New Treatment Approach for Patients With Chronic Myofascial Pain in the Orofacial Muscles Completed NCT02230371 Phase 4 Granisetron;Control (placebo)
40 Plasma Rich in Growth Factors Effectiveness for Myofascial Pain Treatment in Masticatory Muscles: a Randomized Controlled Clinical Trial Completed NCT04040309 Phase 4 Lidocaine injection
41 Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty: A Double-blinded Randomized Control Trial Completed NCT03271151 Phase 4 Cymbalta
42 Neurologic Signatures of Chronic Pain Disorders Completed NCT02747940 Phase 4 flunarizine and/or pregabalin
43 A Randomized, Single-dose, Parallel-group Study to Evaluate the Pharmacokinetic Profiles of Two Formulation of Pregabalin in Healthy Volunteers Under Fasting Conditions Completed NCT03712475 Phase 4 Pregabalin
44 Trigger Point Injection for Myofascial Pain Syndrome in the Low Back (T-PIMPS): A Randomized Controlled Trial. Recruiting NCT04704297 Phase 4 Treatment of Myofascial Pain Syndrome in the low back. This intervention will be based on outcomes of the medications listed below.;Evaluation of functional ability using a patient centered functional score known as the Modified Oswestry Disability Index (MODI). The intervention will be based on outcomes of medications below.;Following up with participants 60-72 hours after treatment in the Emergency Department. This intervention will be based on outcomes of the medications listed below.
45 Efficacy and Tolerability of Micronized and Ultramicronized Palmitoylethanolamide in Fibromyalgia Patients: A Double-blind, Randomized, Placebo-controlled Clinical Trial Recruiting NCT04488926 Phase 4 Standard Therapy;Rescue Drug
46 Magnesium Sulphate Injection in Treatment of Myofascial Trigger Points in Masseter Muscle Recruiting NCT04742140 Phase 4 Magnesium sulfate;Saline
47 Safety Evaluation of Linear and Macrocyclic Gadolinium-Based Contrast Agents for Patients With Mild to Moderate Renal Insufficiency Undergoing Enhanced Magnetic Resonance Imaging (Interventional Prospective Study) Clinical Trial Protocol Recruiting NCT04776187 Phase 4 Gadodiamide;Gadoteric Acid Meglumine Salt
48 Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD) Recruiting NCT04245748 Phase 4 Escitalopram;Duloxetine
49 Anti-CGRP Neutralizing Antibody for Modulation of Neurogenic Inflammation in Trigeminal and Glossopharyngeal Pain Associated With Small Fiber Neuropathy/Fibromyalgia Recruiting NCT04158752 Phase 4 Galcanezumab
50 Effectiveness, Cost-utility and Neurobiological Effects of Low-dose Naltrexone in Patients With Fibromyalgia (INNOVA Project) Not yet recruiting NCT04739995 Phase 4 Low-dose naltrexone

Search NIH Clinical Center for Fibromyalgia

Cochrane evidence based reviews: fibromyalgia

Sources

Genetic Tests for Fibromyalgia

About this section
Sources

Anatomical Context for Fibromyalgia

About this section

MalaCards organs/tissues related to Fibromyalgia:

40
Liver, Cortex, Breast, Skin, Pituitary, Brain, Thyroid
Sources

Publications for Fibromyalgia

About this section

Articles related to Fibromyalgia:

(show top 50) (show all 10815)
# Title Authors PMID Year
1
Immediate Effects of a Telerehabilitation Program Based on Aerobic Exercise in Women with Fibromyalgia. 61 42
33672691 2021
2
Augmentation of EMDR with multifocal transcranial current stimulation (MtCS) in the treatment of fibromyalgia: study protocol of a double-blind randomized controlled exploratory and pragmatic trial. 42 61
33514408 2021
3
Suicidal Ideation Profiles in Patients with Fibromyalgia Using Transdiagnostic Psychological and Fibromyalgia-Associated Variables. 42 61
33396651 2020
4
Pathophysiology of fibromyalgia: a comparison with the tension-type headache, a localized pain syndrome. 61 54
20398011 2010
5
Genetic influences on the dynamics of pain and affect in fibromyalgia. 54 61
20230086 2010
6
Autonomic dysfunction and neuropeptide Y in fibromyalgia. 54 61
20074444 2009
7
Candidate-gene approach in fibromyalgia syndrome: association analysis of the genes encoding substance P receptor, dopamine transporter and alpha1-antitrypsin. 61 54
20074437 2009
8
The relationship between a common catechol-O-methyltransferase (COMT) polymorphism val(158) met and fibromyalgia. 61 54
20074440 2009
9
Polymorphisms of the serotonin-2A receptor and catechol-O-methyltransferase genes: a study on fibromyalgia susceptibility. 61 54
18196244 2008
10
Cerebrospinal fluid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia. 54 61
16936702 2006
11
Corticotropin releasing factor in urine--a possible biochemical marker of fibromyalgia. Responses to massage and guided relaxation. 61 54
16716515 2006
12
Increased expression of N-methyl-D-aspartate receptor subunit 2D in the skin of patients with fibromyalgia. 54 61
16583480 2006
13
Alteration of serotonin transporter density and activity in fibromyalgia. 61 54
16790074 2006
14
alpha1-Antitrypsin and fibromyalgia: new data in favour of the inflammatory hypothesis of fibromyalgia. 61 54
15694694 2005
15
Alpha1-antitrypsin replacement therapy controls fibromyalgia symptoms in 2 patients with PI ZZ alpha1-antitrypsin deficiency. 54 61
15468381 2004
16
Increase in peripheral benzodiazepine receptors on monocytes in fibromyalgia. 54 61
15252208 2004
17
Mutational analysis of serotonin receptor genes: HTR3A and HTR3B in fibromyalgia patients. 61 54
15293096 2004
18
Open trial of mirtazapine in patients with fibromyalgia. 54 61
15467973 2004
19
Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia. 54 61
15370724 2004
20
Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5- HTTLPR) polymorphism, and relationship to anxiety-related personality traits. 54 61
11920428 2002
21
Neuroendocrine and immune aspects of fibromyalgia. 54 61
11543693 2001
22
Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6: a pilot study in fibromyalgia. 54 61
10765933 2000
23
Efficacy and tolerability of tropisetron in primary fibromyalgia--a highly selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia Study Group. 61 54
11028832 2000
24
Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. 54 61
10555044 1999
25
Lower serum activity of prolyl endopeptidase in fibromyalgia is related to severity of depressive symptoms and pressure hyperalgesia. 61 54
9723150 1998
26
Plasma levels on nociceptin in female fibromyalgia syndrome patients. 61 54
10025089 1998
27
Pathogenetic aspects of responsiveness to ondansetron (5-hydroxytryptamine type 3 receptor antagonist) in patients with primary fibromyalgia syndrome--a preliminary study. 54 61
8856622 1996
28
The 5-HT3 blockers in the treatment of the primary fibromyalgia syndrome: a 10-day open study with Tropisetron at a low dose. 61 54
9088121 1996
29
Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. 54 61
7980669 1994
30
Central nervous activity during implicit processing of emotional face expressions in fibromyalgia syndrome. 61
33539799 2021
31
Blood pressure as a predictor of everyday cognitive function in aging adults with and without fibromyalgia. 61
32339069 2021
32
Pain in Axial Spondyloarthritis: Insights from Immunology and Brain Imaging. 61
33781490 2021
33
Daily associations between sleep and opioid use among adults with comorbid symptoms of insomnia and fibromyalgia. 61
33226334 2021
34
Personality and psychopathology heterogeneity in MMPI-2 and health-related features in fibromyalgia patients. 61
33217011 2021
35
Promoting unsupervised walking in women with fibromyalgia: a randomized controlled trial. 61
32544346 2021
36
Effectiveness of Exercise on Fatigue and Sleep Quality in Fibromyalgia: A Systematic Review and Meta-analysis of Randomized Trials. 61
32721388 2021
37
Neural therapy for fibromyalgia: Myth or improving quality of life? 61
32955788 2021
38
Trajectories of change in symptom severity in patients with fibromyalgia: exploratory analyses of a randomised controlled trial. 61
33590330 2021
39
Who Is Seeking Help for Sleep? A Clinical Profile of Patients in a Sleep Psychology Clinic. 61
32405918 2021
40
Fibromyalgia associated with Chagas' disease treated with nutraceuticals. 61
33745580 2021
41
Ultrasound to identify SLE patients with musculoskeletal symptoms who respond best to therapy: The USEFUL longitudinal multicentre study. 61
33792659 2021
42
Fibromyalgia in patients with synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome: prevalence and screening. 61
32949312 2021
43
Adult attention deficit hyperactivity disorder in patients with fibromyalgia syndrome: Assessment and disabilities. 61
33127072 2021
44
Dual trajectories of fatigue and disease activity in an inception cohort of adults with systemic lupus erythematosus over 10 years. 61
33413006 2021
45
Pilot Study of French-Canadian Lifestyle Redesign® for Chronic Pain Management. 61
33393417 2021
46
Chronic fatigue syndrome: Abnormally fast muscle fiber conduction in the membranes of motor units at low static force load. 61
33639451 2021
47
Dual-trajectories of opioid and gabapentinoid use and risk of subsequent drug overdose among Medicare beneficiaries in the United States: a retrospective cohort study. 61
32648951 2021
48
Physical and mental impact of COVID-19 outbreak on fibromyalgia patients. 61
33734970 2021
49
Duloxetine suppresses BMP-4-induced release of osteoprotegerin via inhibition of the SMAD signaling pathway in osteoblasts. 61
33646885 2021
50
Analysis of the measurement properties of the Brazilian-Portuguese version of the Tampa Scale for Kinesiophobia-11 in patients with fibromyalgia. 61
32487449 2021
Sources

Variations for Fibromyalgia

About this section
Sources

Expression for Fibromyalgia

About this section
Search GEO for disease gene expression data for Fibromyalgia.
Sources

Pathways for Fibromyalgia

About this section

Pathways related to Fibromyalgia according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Peptide ligand-binding receptors 65
Show member pathways
 13.35 TSPO TACR1 POMC PNOC OPRM1 NPY
2
cAMP signaling pathway 36
12.18 POMC NPY GRIN2D BDNF
3
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.04 TNF IL6 IGF1 CXCL8 BDNF
4
Spinal Cord Injury 1
11.8 TNF TACR1 IL6 CXCL8 BDNF
5
Interleukin-4 and 13 signaling 65
11.71 TNF POMC OPRM1 IL6 CXCL8
6
Glucocorticoid receptor regulatory network 1
11.67 POMC IL6 CXCL8
7
Pertussis 36
11.62 TNF IL6 CXCL8
8
Adipocytokine signaling pathway 36
11.57 TNF POMC NPY
9
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.51 TNF IL6 CXCL8
10
Legionellosis 36
11.44 TNF IL6 CXCL8
11
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.43 TNF TACR1 SLC6A4 IL6 HTR3A HTR2A
12
Malaria 36
11.37 TNF IL6 CXCL8
13
Interleukin-10 signaling 65
11.34 TNF IL6 CXCL8
14
Transcription_Role of VDR in regulation of genes involved in osteoporosis 23
11.29 TNF IL6 IGF1
15
Lung fibrosis 1
11.15 TNF SERPINA1 IL6 IGF1 CXCL8
16
Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics 60
11.03 SLC6A4 HTR3A HTR2A
17
Overview of nanoparticle effects 1
10.74 TNF IL6 CXCL8 CRP
18
Glucocorticoid Pathway (HPA Axis), Pharmacodynamics 60
10.37 POMC CRH
Sources

GO Terms for Fibromyalgia

About this section

Cellular components related to Fibromyalgia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10 TNF SERPINA1 POMC PNOC NPY IL6
2 synapse GO:0045202 9.87 SLC6A4 PNOC NPY HTR3A HTR2A GRIN2D
3 extracellular space GO:0005615 9.85 TNF SERPINA1 POMC NPY IL6 IGF1
4 dendrite GO:0030425 9.8 PNOC OPRM1 HTR2A COMT BDNF
5 axon GO:0030424 9.77 OPRM1 HTR3A HTR2A COMT BDNF
6 integral component of presynaptic membrane GO:0099056 9.26 SLC6A4 OPRM1 HTR3A HTR2A
7 integral component of postsynaptic membrane GO:0099055 8.92 SLC6A4 OPRM1 HTR3A HTR2A

Biological processes related to Fibromyalgia according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.06 TACR1 POMC PNOC OPRM1 NPY HTR2A
2 signal transduction GO:0007165 10 TACR1 POMC PNOC OPRM1 IL6 IGF1
3 response to drug GO:0042493 9.91 TSPO SLC6A4 HTR2A CRH COMT
4 cytokine-mediated signaling pathway GO:0019221 9.89 TNF POMC OPRM1 IL6 CXCL8
5 cellular response to lipopolysaccharide GO:0071222 9.86 TSPO TNF IL6 CXCL8
6 inflammatory response GO:0006954 9.85 TNF TACR1 IL6 CXCL8 CRP CRH
7 memory GO:0007613 9.8 SLC6A4 HTR2A BDNF
8 chemical synaptic transmission GO:0007268 9.8 PNOC NPY HTR3A HTR2A CRH
9 negative regulation of tumor necrosis factor production GO:0032720 9.79 TSPO POMC IGF1
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.79 TNF IL6 IGF1
11 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.78 OPRM1 NPY HTR2A
12 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.77 TACR1 OPRM1 HTR2A
13 excitatory postsynaptic potential GO:0060079 9.77 OPRM1 HTR3A GRIN2D
14 positive regulation of smooth muscle cell proliferation GO:0048661 9.76 TNF IL6 IGF1
15 neuropeptide signaling pathway GO:0007218 9.73 POMC PNOC OPRM1 NPY
16 response to cocaine GO:0042220 9.72 OPRM1 HTR3A CRH
17 acute-phase response GO:0006953 9.7 SERPINA1 IL6 CRP
18 positive regulation of gene expression GO:0010628 9.7 TNF SLC6A4 IL6 IGF1 CXCL8 CRP
19 regulation of sensory perception of pain GO:0051930 9.65 OPRM1 GRIN2D COMT
20 vascular endothelial growth factor production GO:0010573 9.58 TNF IL6
21 serotonin receptor signaling pathway GO:0007210 9.57 HTR3A HTR2A
22 positive regulation of appetite GO:0032100 9.54 OPRM1 NPY
23 positive regulation of glial cell proliferation GO:0060252 9.5 TSPO TNF IL6
24 negative regulation of lipid storage GO:0010888 9.13 TNF IL6 CRP
25 response to pain GO:0048265 8.92 TSPO TACR1 CRH COMT

Molecular functions related to Fibromyalgia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.46 POMC NPY IGF1 CRH
2 neuropeptide hormone activity GO:0005184 9.13 PNOC NPY CRH
3 serotonin binding GO:0051378 8.8 SLC6A4 HTR3A HTR2A
Sources

Sources for Fibromyalgia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....